Introduction {#s1}
============

CRC is a very common gastrointestinal tumor with high incidence and mortality. It was estimated that more than 1.8 million new colorectal cancer cases and 0.88 million deaths will occur in 2018, accounting for about 1 in 10 cancer about incidence and mortality ([@B1]). CRC patients usually show a survival rate of \<5 years due to early metastasis. Although treatments (such as surgery, radiotherapy, chemotherapy, and targeted therapy) have been developed fleetly, high recurrence, and poor prognosis remain troubling issues ([@B2]). Although various biomarkers have been discovered and were associated with the occurrence, progression and prognosis of colorectal cancer to date ([@B3]), their reliability remains controversial. Consequently, it is urgent to screen new potential diagnostic and prognostic biomarkers or therapeutic targets for CRC.

MicroRNAs (miRNAs), a vital component of the non-coding RNA family, are approximately made up of 18--25 nucleotides, which almost function via binding 3′ untranslated regions(UTR)or 5′UTR of mRNA to suppress translation and promote mRNA cleavage ([@B4]). Along with the advances of human genome-sequencing technology, a great number of miRNAs have been abundantly discovered. Increasing evidence demonstrated that miRNAs regulated various oncogenesis processes including cellular proliferation, angiogenesis, differentiation, and apoptosis by binding oncogenes or tumor suppresser genes ([@B5]). Zhang et al. displayed miRNA-519b-3p functioned as a tumor suppressor miRNA to suppress colorectal cancer cell proliferation and invasion by regulating the umtck/wnt signaling pathway ([@B6]). Wang et al. exhibited that miRNA-496 accelerated epithelial-mesenchymal transition and migration of CRC via targeting RASSF6, which was involved in Wnt-pathway ([@B7]). Huang et al. demonstrated miR-506 inhibited cell proliferation, invasion, and migration of CRC via reducing NR4A1 expression ([@B8]). Studies on miRNA in colorectal cancer are far more than that, there are also some studies on miRNA as prognostic factors, including single, and multiple combinations. Although TCGA database has been used to construct the miRNA signature prognostic models for colon cancer ([@B9], [@B10]), there are still some shortcomings with no miRNAs matures, model validation, and risk assessment.

In the present study, we constructed, verified and assessed a novel five-miRNA signature that predicted effectively over survival of CRC patients derived from TCGA database. Functional enrichment analysis revealed potential biological functions and signal pathways of five-miRNA signature associated with cancer, which enhances our understanding to molecular mechanisms of model in CRC.

Materials and Methods {#s2}
=====================

Data Download and Processing
----------------------------

The miRNA expression information \[Case (455): Primary Site (Colon and Rectum), Program (TCGA),Project (TCGA-COAD and TCGA-READ), Disease Type (Adenomas and Adenocarcinomas); Files(473): Data Category (Transcriptome Profiling), Data Type (Isoform Expression Quantification)\], mRNA expression information \[Case (472): Primary Site (Colon and Rectum), Program (TCGA), Project (TCGA-COAD and TCGA-READ), Disease Type (Adenomas and Adenocarcinomas); Files (530): Data Category (Transcriptome Profiling), Data Type (Gene Expression Quantification)\] and their related clinical information (476) (Data Category: Clinical, Data Format: BCR XML) ([Table 1](#T1){ref-type="table"}) of all colorectal cancer samples were downloaded from The Cancer Genome Atlas (TCGA) official website (<https://cancergenome.nih.gov/>) on July 3, 2019, the former of which contained 464 tumor samples and 9 normal samples, the latter included 488 tumor samples and 42 normal samples. The Fasta format sequences of all mature miRNA sequences (mature.fa) were downloaded from the miRBase website (<http://www.mirbase.org/>). We combined these two sets of data in the Perl language to obtain expression profile information for each mature miRNA.

###### 

Summary of patient cohort information.

  **Variables**           **Case**   **Percentage**
  ----------------------- ---------- ----------------
  **GENDER**                         
  Male                    256        53.78%
  Female                  220        46.22%
  **AGE (YEARS)**                    
  Range                   31--90     
  Median                  68         14.29
  **RACE**                           
  ASIAN                   9          1.89%
  BLACK                   52         10.92%
  WHITE                   219        46.01%
  Unknown                 196        41.18%
  **CLINICAL STAGE**                 
  Stage I                 85         17.86%
  Stage II                180        37.82%
  Stage III               126        26.47%
  Stage IV                70         14.71%
  Unknown                 15         3.15%
  **T STAGE**                        
  T1+Tis                  15         3.15%
  T2                      86         18.07%
  T3                      324        68.07%
  T4                      51         10.71%
  **LYMPH NODE STATUS**              
  N0                      282        59.24%
  N1                      114        23.95%
  N2                      80         16.81%
  Nx                      1          0.21%
  **METASTATIC**                     
  M0                      355        74.58%
  M1                      69         14.50%
  Mx                      45         9.45%
  Unknown                 7          1.47%
  **CANCER TYPE**                    
  COAD                    385        80.88%
  READ                    91         19.12%

Identification of Differentially Expressed miRNAs, mRNA, and Their Combination With Patient Survival Data
---------------------------------------------------------------------------------------------------------

We used R language 3.6.1 version edgeR package to compare the miRNA and mRNA expression of tumor group with normal group and normalize the expression profile of miRNAs and mRNA, whose mean value was \>1, the screening criteria were corrected *p* value (FDR) \< 0.05 and \|log2FC\|\>1 ([@B11]). We selected the clinical information of patients with survival time ≥30 days and combined it with differentially expressed and standardized miRNA and mRNA expression profiles.

Grouping of Samples and Construction, Validation, and Evaluation of Prognostic Models
-------------------------------------------------------------------------------------

We used the R language 3.6.1 version "caret" package to randomly divide the samples with complete survival information and differentially expressed miRNA expression profiles into two groups (train group and test group), and performed univariate Cox regression analysis of miRNAs for the train group.

In order to reduce the number of miRNAs with similar expression, miRNAs with *p* value \< 0.005 were subjected to a stepwise multivariate Cox regression to construct the prognostic model. In the multivariate Cox regression analysis, we took advantage of the function of "Coxph" and "direction = both" in R language survival package ([@B12]). Then, the risk score of a prognostic miRNA signature comprising multiple miRNAs was established based on the summation of the product of each miRNA and its coefficient. Furthermore, we tested the Proportional Hazards Assumption in Cox model. This model was used to evaluate the survival prognosis of each patients in train group, test group, entire group using Kaplan-Meier curve, and log-rank test according to median value grouping of risk score, namely high risk group, and low risk group. The predictive power of the miRNA signature was assessed by calculating AUC of 3 years dependent ROC curve using "survivalROC" package ([@B13]).

Independent Prognostic Ability of the miRNA Signature Including Other Clinical Variables
----------------------------------------------------------------------------------------

The relationship between the prognostic miRNA signature and patients\' overall survival was analyzed in the train group by univariate Cox regression, as well as clinical variables (including age, gender, and clinical stage, lymph nodes, distant metastasis). Variables with *p* value \< 0.05 in univariate Cox regression were further used for multivariate Cox regression analysis to determine whether they could function as independent prognostic factors. In order to compare the predictive power of this risk model compared to other clinical characteristics, we have drawn ROC curves for this model risk score and clinical characteristics. In addition, we tested the correlation of each miRNA to clinical features by using the SPSS 21.0 chi-square test, with a *p*-value of \< 0.05 being considered meaningfully.

Target Genes Prediction of miRNA Signature and Their Potential Functions
------------------------------------------------------------------------

We downloaded the miRNA prediction database from three miRNA target gene prediction websites including miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/>), targetScan (<http://www.targetscan.org>) and miRDB (<http://www.mirdb.org/>), and used the Perl language to find the target genes of miRNA signature which are covered in at least 2 databases, meanwhile, utilizing the Venn diagram, and Cytoscape 3.6.1 to map the relationship between the miRNA and these target genes. To clarify whether the target genes of these miRNAs are likely to participate in the progression of colorectal cancer, we taken the intersection of these target genes and differentially expressed genes in colorectal cancer. All of these intersection genes obtained were analyzed by Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway and Gene Ontology (GO) enrichment analysis through the R language "clusterProfiler" package ([@B14]) and the "org.Hs.eg.db" package, The *p* adjust \< 0.05 and *q* value \< 0.05 was set as the cut-off criteria.

Screening of Hub Genes and Survival Related Gene
------------------------------------------------

The PPI network of the STRING database (<https://string-db.org/>) ([@B15]) was applied to unearth the relationship between the target genes, the parameter of settings the medium confidence is 0.400. Then, the network relationship file was downloaded and the top 10 hub genes were identified in accordance with Cytoscape 3.6.1 and its plug-in (degrees ranking of cytoHubba). Meanwhile, The Kaplan-Meier method was used to check whether the intersection gene is related to over survival, log rank test \< 0.05.

Statistical Analysis
--------------------

All statistical analyses are based on R language 3.6.1 version and attached packages.

Results {#s3}
=======

Identification of Differentially Expressed miRNAs and mRNAs
-----------------------------------------------------------

Based on this screening criteria, miRNA mature expression profiles between 464 tumor samples and 9 normal samples showed 502 differentially expressed miRNAs (DEmiRNAs), of which 343 were up-regulated and 159 were down-regulated ([Figure 1](#F1){ref-type="fig"}). mRNA expression profiles between 488 tumor samples and 42 normal samples showed 5,540 differentially expressed mRNAs (DEmRNAs), of which 2992 were up-regulated and 2,548 were down-regulated, displayed in [Supplemental Table 1](#SM3){ref-type="supplementary-material"}.

![Unsupervised hierarchical clustering heatmap based on the differentially expressed miRNAs between 464 colorectal cancer tissues and 9 normal tissues.](fonc-09-01207-g0001){#F1}

Construction of the Predictive Five-miRNA Signature
---------------------------------------------------

The entire group (*N* = 421) with miRNA mature expression profiles was randomly divided into train group (*N* = 212) ([Supplemental Table 2](#SM4){ref-type="supplementary-material"}) and test group (*N* = 209) ([Supplemental Table 3](#SM5){ref-type="supplementary-material"}). The univariate Cox regression analysis displayed that a total of thirty-two miRNAs were found to be associated with patients\' overall survival (*p* value \< 0.05) in the train group. For the reliability of the model, eight miRNAs (*p* value \< 0.005) were selected for further analysis ([Table 2](#T2){ref-type="table"}). Kaplan-Meier method pointed out hsa-miR-10b-3p, hsa-miR-216a-5p, and hsa-miR-485-5p of eight miRNAs were associated with patients\' overall survival (*p* value \< 0.05; [Figure 2](#F2){ref-type="fig"}), however, the high expression of hsa-miR-485-5p with poor prognosis and the fact that hsa-miR-485-5p exhibited low expression in tumors is contradictory. Therefore, the remaining seven miRNAs were targeted for further analysis.

###### 

Univariate and multivariate Cox regression of differentially expressed miRNAs.

                    **Univariate Cox regression**   **Multivariate Cox regression**                                                   
  ----------------- ------------------------------- --------------------------------- ------- ------- ------- ------- ------- ------- -------
  hsa-miR-485-5p    1.292                           1.124                             1.485   0.000                                   
  hsa-miR-216a-5p   1.069                           1.031                             1.109   0.000                                   
  hsa-miR-187-3p    1.044                           1.019                             1.069   0.000   0.031   1.031   1.001   1.062   0.041
  hsa-miR-10b-3p    1.016                           1.006                             1.027   0.003   0.011   1.011   0.999   1.023   0.067
  hsa-miR-32-5p     1.007                           1.003                             1.012   0.003   0.008   1.008   1.003   1.013   0.003
  hsa-miR-9-5p      1.000                           1.000                             1.000   0.003   0.000   1.000   1.000   1.000   0.008
  hsa-miR-5091      1.194                           1.059                             1.346   0.004   0.177   1.194   1.045   1.363   0.009
  hsa-miR-5683      1.004                           1.001                             1.006   0.005                                   

![Three miRNAs associated with overall survival in CRC patients using Kaplan--Meier curves and log-rank tests. The patients were stratified into high and low expression groups according to the median expression of each miRNA. **(A)** hsa-miR-10b-3p. **(B)** hsa-miR-216a-5p. **(C)** hsa-miR-485-5p.](fonc-09-01207-g0002){#F2}

Based on the previous research, Five (hsa-miR-5091, hsa-miR-10b-3p, hsa-miR-9-5p, hsa-miR-187-3p, hsa-miR-32-5p) of the seven candidate miRNAs therein were finally screened out ([Table 2](#T2){ref-type="table"}) by stepwise multivariate Cox regression analysis, then a predictive miRNA signature model was established on the summation of the product of each miRNA and its coefficient in multivariate Cox regression as follows: miRNA signature risk score = (0.1769 × expression of hsa-miR-5091) + (0.0110 × expression of hsa-miR-10b-3p) + (0.0001 × expression of hsa-miR-9-5p) + (0.0305 × expression of hsa-miR-187-3p) + (0.0076 × expression of hsa-miR-32-5p). In addition, the results testing the Proportional Hazards Assumption in Cox model demonstrated that all the *P* values are higher than 0.05, which means that they meet the PH test ([Supplemental Table 4](#SM6){ref-type="supplementary-material"}).

Prediction of the Five-miRNA Signature for Over Survival in the Train Group, Test Group, and Entire Group
---------------------------------------------------------------------------------------------------------

Based on median value grouping of risk score. Kaplan-Meier curves shown high risk group had an obviously poorer overall survival compared to low risk group in the train group (*p* = 1.001E-02), test group (*p* = 4.164E-04) and entire group (*p* = 2.12E-05; [Figures 3A--C](#F3){ref-type="fig"}). The train group shown overall survival of 5 years for patients with high and low risk group were 60.0 and 72.8%, respectively. The test group demonstrated that overall survival of 5 years for patients with high and low risk group were 39.9 and 62.7%, respectively. The entire group displayed that overall survival of 5 years for patients with high and low risk group were 53.0 and 62.8%, respectively.

![Validation and evaluation of the predictive five-miRNA signature. Kaplan-Meier curves in the train group **(A)**, test group **(B)**, entire group **(C)**; The AUC of three years dependent curve in the train group **(D)**, test group **(E)**, entire group **(F)**, Survival status in high and low risk patients for train group **(G)**, test group **(H)**, entire group **(I)**, red dots represent death, green dots represent alive.](fonc-09-01207-g0003){#F3}

Evaluation of the Five-miRNA Signature for Over Survival in the Train Group, Test Group, and Entire Group
---------------------------------------------------------------------------------------------------------

The AUC of 3 years dependent ROC for the five-miRNA signature achieved 0.790, 0.679, 0.744, respectively, in the train group, test group and entire group ([Figures 3D--F](#F3){ref-type="fig"}), which demonstrated the better performance of model in predicting CRC patient survival risk. In addition, in the three groups, the patients with high risk score had higher mortality rates than low ([Figures 3G--I](#F3){ref-type="fig"}).

Independence of the Five-miRNA Signature Considering Other Clinical Factors
---------------------------------------------------------------------------

Univariate Cox regression analysis exhibited that the five-miRNA signature was evidently associated with patients\' overall survival (hazard ratio HR = 1.286, confidence interval 95% CI = 1.164--1.420, *p* = 6.719E-07; [Table 3](#T3){ref-type="table"}). Multivariate Cox regression analysis pointed out that the five-miRNA signature remained independent with overall survival considering other conventional clinical factors (HR = 1.326, 95% CI = 1.168--1.505, *p* = 1.23E-05), such as clinical stage, T stage, Lymph-node status, distant metastasis, which makes it possible to be a prognostic marker for CRC in the future. Meanwhile, distant metastasis was also found to be an independent prognostic factor (HR = 2.976, 95% CI = 1.285--6.891, *p* = 0.01). The ROC curves for this model risk score and clinical characteristics demonstrated that risk score (0.777), clinical stage (0.810), T stage (0.707), Lymph-node status (0.725), and distant metastasis (0.744) had a high predictive ability ([Figure 4](#F4){ref-type="fig"}). In addition, the results about the correlation of each miRNA to clinical features demonstrated hsa-miR-10b-3p was associated with T stage (*p* = 0.011), hsa-miR-9-5p was associated with age (*p* = 0.032), and clinical stage (*p* = 0.049), hsa-mir-3189 was associated with Metastasis (*p* = 0.002) and clinical stage (*p* = 0.042; [Table 4](#T4){ref-type="table"}), which further suggested that these miRNAs do have a close relationship with some clinical features.

###### 

Univariate and multivariate Cox regression of clinical features.

  **Clinical features**              **Univariate Cox regression**   **Multivariate Cox regression**                                             
  ---------------------------------- ------------------------------- --------------------------------- -------- ------- ------- ------- -------- -------
  Age (continuous variable)          1.017                           0.986                             1.050    0.290                            
  Gender (male vs. female)           1.210                           0.594                             2.467    0.600                            
  Clinical stage (III+IV vs. I+II)   7.872                           3.010                             20.588   0.000   4.902   0.472   50.935   0.183
  T stage (T3+4 vs. T1+2)            6.694                           0.910                             49.250   0.062                            
  M (M1 VS M0)                       7.920                           3.816                             16.440   0.000   2.977   1.286   6.892    0.011
  N (N1+2 vs. N0)                    6.585                           2.693                             16.102   0.000   0.996   0.130   7.666    0.997
  Five-miRNA signature               1.286                           1.165                             1.420    0.000   1.326   1.168   1.505    0.000

![Comparison of risk score and clinical features in predicting the accuracy of patients\' survival prognosis.](fonc-09-01207-g0004){#F4}

###### 

The correlation of each miRNA to clinical features.

  **Variables**           **Numbers**   **hsa-miR-5091**   **χ^2^ test *P* value**   **hsa-miR-10b-3p**   **χ^2^ test *P* value**   **hsa-miR-9-5p**   **χ^2^ test P value**   **hsa-miR-187-3p**   **χ^2^ test *P* value**   **hsa-mir-3189**   **χ^2^ test *P* value**                          
  ----------------------- ------------- ------------------ ------------------------- -------------------- ------------------------- ------------------ ----------------------- -------------------- ------------------------- ------------------ ------------------------- ---- ------- ---- ---- -------
  **GENDER**                                                                                                                                                                                                                                                                                      
  Female                  81            46                 35                        0.12                 43                        38                 0.425                   44                   37                        0.334              40                        41   0.834   41   40   0.4
  Male                    108           49                 59                                             51                        57                                         51                   57                                           55                        53           48   60   
  **AGE AT DIAGNOSIS**                                                                                                                                                                                                                                                                            
  \>60                    136           69                 67                        0.836                66                        70                 0.595                   75                   61                        0.032              72                        64   0.238   59   77   0.102
  ≤ 60                    53            26                 27                                             28                        25                                         20                   33                                           23                        30           30   23   
  **T STAGE**                                                                                                                                                                                                                                                                                     
  T1+2                    40            23                 17                        0.303                27                        13                 0.011                   21                   19                        0.75               25                        15   0.081   20   20   0.678
  T3+4                    149           72                 77                                             67                        82                                         74                   75                                           70                        79           69   80   
  **METASTASIS**                                                                                                                                                                                                                                                                                  
  M0                      155           78                 77                        0.973                79                        76                 0.469                   81                   74                        0.242              83                        72   0.054   81   74   0.002
  M1                      34            17                 17                                             15                        19                                         14                   20                                           12                        22           8    26   
  **LYMPH NODE STATUS**                                                                                                                                                                                                                                                                           
  N0                      103           53                 60                        0.72                 54                        49                 0.418                   58                   45                        0.069              55                        48   0.346   54   49   0.108
  N1-2                    86            42                 44                                             40                        46                                         37                   49                                           40                        46           35   51   
  STAGE                                                                                                                                                                                                                                                                                           
  I+II                    100           50                 50                        0.939                52                        48                 0.509                   57                   43                        0.049              52                        48   0.613   54   46   0.044
  III+IV                  89            45                 44                                             42                        47                                         38                   51                                           43                        46           35   54   

Prediction of Target Genes for the Five miRNAs
----------------------------------------------

The target genes regulated by the five miRNAs, were predicted in at least 2 databases. To further enhance the reliability of the bioinformatic analysis, the overlapping target genes were identified. The results indicated that 41, 272, 701, 31, and 752 overlapping genes were identified for hsa-miR-5091, hsa-miR-10b-3p, hsa-miR-9-5p, hsa-miR-187-3p, hsa-miR-32-5p, respectively, by the three databases above, which were shown using Venn diagram ([Figure 5](#F5){ref-type="fig"}) and network map of miRNA-target genes ([Supplemental Figure 1](#SM1){ref-type="supplementary-material"}). A total of 1,672 target genes was predicted for the five miRNAs. To clarify whether the target genes of these miRNAs are likely to participate in the progression of CRC, the above obtained 5540 DEmRNAs (up-regulated 2992, down-regulated 2548) was used for analysis. The intersection of target mRNAs for down-regulated miRNAs (hsa-miR-5091, hsa-miR-187-3p) and upregulated mRNAs, and target mRNAs for upregulated miRNAs (hsa-miR-32-5p, hsa-miR-10b-3p, hsa-miR-9-5p) and downregulated mRNAs were taken. The results were performed on a total of 246 genes including 12 up-regulated genes, 234 down-regulated genes, respectively ([Supplemental Figure 2](#SM2){ref-type="supplementary-material"}). The sub network between the five miRNAs and their 246 target genes was shown in [Figure 6](#F6){ref-type="fig"}.

![Venn diagram of target genes for five miRNAs. **(A)** hsa-miR-10b-3p, **(B)** hsa-miR-187-3p, **(C)** hsa-miR-5091, **(D)** hsa-miR-9-5p, **(E)** hsa-miR-32-5p.](fonc-09-01207-g0005){#F5}

![Sub network map of miRNA regulating mRNA. The hexagon represents miRNA. The circle stands for mRNA. Red means upregulated, blue means downregulated, and green means both.](fonc-09-01207-g0006){#F6}

Functional Enrichment Analysis of Target Genes Associated CRC
-------------------------------------------------------------

The results of GO annotation about the target genes associated CRC are 234 ([Supplemental Table 5](#SM7){ref-type="supplementary-material"}). The top fifteen terms from the GO results: biological process (BP), cellular component (CC), and molecular function (MF) were demonstrated in dotplot ([Figures 7A--C](#F7){ref-type="fig"}). In the three categories, BP analysis mostly include axon development, axonogenesis, and stem cell differentiation, CC analysis was mainly contained synaptic membrane, postsynaptic membrane and neuronal cell body, MF analysis mainly contained metal ion transmembrane transporter activity, transcriptional activator activity and DNA binding, ion channel binding. The results of KEGG pathways about the target genes associated CRC are 18 ([Table 5](#T5){ref-type="table"}), of which counts \> 10 were mainly enriched in the cGMP-PKG signaling pathway, cAMP signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction In addition, to provide a readable graphic representation of the complex relationship between target genes and relative KEGG pathway, the "pathway-gene network" and "pathway-pathway network" was also shown in [Figures 7D--F](#F7){ref-type="fig"}.

![Functional enrichment analysis of target genes associated CRC. **(A)** BP, **(B)** CC, **(C)** MF, **(D)** dotplot of KEGG signal pathway shown the counts of genes, **(E)** cnetplot of KEGG signal pathway shown the "pathway-gene" network, **(F)** emapplot of KEGG signal pathway shown the "pathway-pathway" network.](fonc-09-01207-g0007){#F7}

###### 

KEGG pathways of target genes associated CRC.

  **ID**     **Description**                           **P Adjust**   **Q value**   **Count**   **Gene ID**
  ---------- ----------------------------------------- -------------- ------------- ----------- ---------------------------------------------------------------------------
  hsa04022   cGMP-PKG signaling pathway                0.00028        0.000212      12          AKT3/EDNRB/ADCY9/ITPR1/ATP2B4/ADRB1/KCNMB2/PRKG2/ADCY5/MYLK/SLC8A1/MEF2C
  hsa04713   Circadian entrainment                     0.000397       0.0003        9           RPS6KA5/PER1/GRIN2A/ADCY9/ITPR1/GRIA1/CAMK2A/PRKG2/ADCY5
  hsa04024   cAMP signaling pathway                    0.001032       0.000782      12          AKT3/GRIN2A/ADCY9/ATP2B4/HHIP/SLC9A1/GRIA1/CAMK2A/ACOX1/ADRB1/CHRM2/ADCY5
  hsa04261   Adrenergic signaling in cardiomyocytes    0.001032       0.000782      10          RPS6KA5/AKT3/ADCY9/ATP2B4/SLC9A1/CAMK2A/ADRB1/ADCY5/SLC8A1/CACNB2
  hsa04020   Calcium signaling pathway                 0.001443       0.001093      11          GRIN2A/EDNRB/ADCY9/ITPR1/ATP2B4/CAMK2A/ADRB1/PDE1A/CHRM2/MYLK/SLC8A1
  hsa04971   Gastric acid secretion                    0.001615       0.001223      7           ADCY9/ITPR1/SLC9A1/KCNK10/CAMK2A/ADCY5/MYLK
  hsa04970   Salivary secretion                        0.004453       0.003373      7           ADCY9/ITPR1/ATP2B4/SLC9A1/ADRB1/PRKG2/ADCY5
  hsa04924   Renin secretion                           0.006429       0.00487       6           PTGER4/ITPR1/ADRB1/PDE1A/PRKG2/ADCY5
  hsa04371   Apelin signaling pathway                  0.008483       0.006426      8           AKT3/ADCY9/ITPR1/SLC9A1/ADCY5/MYLK/SLC8A1/MEF2C
  hsa05014   Amyotrophic lateral sclerosis (ALS)       0.009933       0.007525      5           GRIN2A/NEFL/NEFM/NEFH/GRIA1
  hsa04923   Regulation of lipolysis in adipocytes     0.012842       0.009728      5           AKT3/ADCY9/ADRB1/PRKG2/ADCY5
  hsa04540   Gap junction                              0.015926       0.012064      6           ADCY9/ITPR1/ADRB1/PDGFD/PRKG2/ADCY5
  hsa04925   Aldosterone synthesis and secretion       0.025762       0.019515      6           ADCY9/ITPR1/ATP2B4/CAMK2A/ADCY5/SCARB1
  hsa04072   Phospholipase D signaling pathway         0.04312        0.032663      7           AKT3/ADCY9/MS4A2/DGKB/PDGFD/ADCY5/KITLG
  hsa04725   Cholinergic synapse                       0.04312        0.032663      6           AKT3/ADCY9/ITPR1/CAMK2A/CHRM2/ADCY5
  hsa04724   Glutamatergic synapse                     0.04312        0.032663      6           GRIN2A/ADCY9/ITPR1/GRIA1/ADCY5/GRIK3
  hsa04921   Oxytocin signaling pathway                0.04312        0.032663      7           ADCY9/ITPR1/CAMK2A/ADCY5/MYLK/MEF2C/CACNB2
  hsa04080   Neuroactive ligand-receptor interaction   0.046345       0.035106      11          GRIN2A/EDNRB/PTGER4/NPY4R/GRIA1/S1PR1/NR3C1/P2RY13/ADRB1/CHRM2/GRIK3

Hub Genes of PPI Network and Survival Related Target Genes
----------------------------------------------------------

Total of 244 of the 246 target genes were filtered into the target genes PPI network complex, containing 178 nodes and 326 edges, 10 hub gene (ESR1, ADCY9, MEF2C, NRXN1, ADCY5, FGF2, KITLG, GATA1, GRIA1, KAT2B) were screened according to Cytoscape 3.6.1 and its plug-in (degree ranking of cytoHubba) ([Figure 8](#F8){ref-type="fig"} and [Table 6](#T6){ref-type="table"}). In addition, Kaplan-Meier method showed that the expression of 18 of the 246 genes (AHCYL2, AKR1B10, CBFA2T3, CCNJL, CCR9, CLIC5, DPP10, FAM46C, GATA1, IQGAP2, MAN1A1, MIER1, NR5A2, PHLPP2, PTGER4, RBM47, RPS6KA5, TSPAN11) were positively associated with survival prognosis, however, the high expression of SRCIN1 shown a poorer over survival ([Figure 9](#F9){ref-type="fig"}).

![Hub genes of PPI network. The darker the color, the bigger the degrees.](fonc-09-01207-g0008){#F8}

###### 

Identification of hub genes by cytoHubba.

  **Node_name**   **MCC**   **DMNC**   **MNC**   **Degree**   **EPC**   **Bottle Neck**   **Ec Centricity**   **Closeness**   **Radiality**   **Betweenness**   **Stress**   **Clustering Coefficient**
  --------------- --------- ---------- --------- ------------ --------- ----------------- ------------------- --------------- --------------- ----------------- ------------ ----------------------------
  ESR1            40        0.238      11        17           57.77     46                0.101               67.513          10.95           7030.605          17450        0.103
  ADCY9           742       0.282      14        14           56.906    4                 0.113               59.613          10.577          1678.562          6756         0.275
  MEF2C           38        0.255      11        13           57.288    14                0.113               61.663          10.735          2113.807          7622         0.192
  NRXN1           44        0.321      8         13           44.099    20                0.113               54.98           10.317          3224.563          11316        0.179
  ADCY5           739       0.337      12        13           56.085    13                0.113               56.846          10.453          1075.731          4490         0.295
  FGF2            19        0.256      7         12           57.027    15                0.101               63.513          10.826          2905.838          9030         0.106
  KITLG           32        0.321      8         12           56.272    9                 0.09                60.182          10.639          1839.913          5646         0.167
  GATA1           67        0.419      10        11           56.982    8                 0.101               58.69           10.566          1203.977          3882         0.382
  GRIA1           22        0.329      7         11           54.01     26                0.113               61.78           10.803          3086.888          10038        0.164
  KAT2B           32        0.402      7         11           53.712    9                 0.101               57.856          10.498          1381.704          4194         0.2

![Target genes associated with over survival.](fonc-09-01207-g0009){#F9}

Discussion {#s4}
==========

Colorectal cancer is a highly malignant tumor, which is particularly prone to liver and lung metastasis, seriously affecting the survival prognosis of patients ([@B16]). Therefore, finding a prognostic marker with high specificity and sensitivity is becoming more and more urgent for patients. Extensive evidence displayed miRNAs can regulate the expression of abundant genes, playing critical roles in many biological processes of human malignant tumor ([@B17]). Especially, recent studies have revealed that distinct miRNA-expression profiles seriously affected the development and progression of CRC ([@B18], [@B19]). At present, several miRNAs are known to be used as potential prognostic indictors in various cancers, including miR-191 ([@B20]), miR-1908 ([@B21]), miR-200c ([@B22]), and miR-217 ([@B23]). However, overwhelming studies manifested that multiple miRNA signature have bigger advantages than single miRNA on the hand of statistically robust analysis. Thence before our study, there have been a lot of prognostic markers based on multiple miRNA signature in tumors ([@B24]--[@B26]), especially colorectal cancer ([@B9], [@B10], [@B27]). There are many differences between our research and previous studies yet, such as research methods, sample size, and most importantly, we use miRNA matures and sample groupings to validate the model.

In the current study, we download mature miRNA expression profiles and corresponding patients\' clinical information of CRC from TCGA database. By using the R language edgeR package for the differential analysis, 502 DEmiRNAs were obtained. All the patients were randomly divided into train group and test group, then a five-miRNA signature model (hsa-miR-5091, hsa-miR-10b-3p, hsa-miR-9-5p, hsa-miR-187-3p, hsa-miR-32-5p) was constructed by univariate Cox regression and stepwise multivariate Cox regression in train group. Meanwhile, a five-miRNA signature was validated in test group and entire group. Based on median value grouping of risk score. Kaplan-Meier curves shown high risk group had an obviously poorer overall survival compared to low risk group in the three group. Evaluation of the five-miRNA signature for over survival in the three group by ROC curve displayed better predictive power. Univariate Cox regression and multivariate Cox regression analysis also pointed out that the five-miRNA signature remained independent with overall survival considering other conventional clinical factors for CRC patients. Most of these five miRNAs have been reported to participate in the research progress of various tumors. Lu et al. demonstrated that the expression level of mir-10b-3p was obviously upregulated in tumor and serum samples of esophageal cancer (ESCC) patients. The expression level of mir-10b-3p is not only correlated with lymph node metastasis and clinical staging, but also serves as an independent prognostic biomarker for overall survival of ESCC patients. Augmented expression of mir-10b-3p stimulates cell proliferation, invasion, and migration through directly combining the FOXO3 3\'UTR in ESCC ([@B28]). Chen et al. shown that miR-9-5p expression was upregulated in prostate cancer cells, functioned as oncogene role in the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of prostate cancer cells by binding StarD13 ([@B29]). Dou et al. demonstrated that miR-187-3p was lowly expressed in hepatic carcinoma (HCC) tissues and cell lines, and was not only correlated with clinical stage and metastasis of HCC, but also accelerated effects of hypoxia on EMT of HCC cells. Furthermore, miR-187-3p suppressed EMT process in HCC via regulating S100A4 ([@B30]). Fu et al. reported that miR-32-5p was markedly upregulated in the HCC multidrug-resistant cell line (Bel/5-FU). Overexpression of miR-32-5p demonstrated a worse prognosis, miR-32-5p regulated the PI3K/Akt pathway via inhabiting PTEN and leaded to multidrug resistance by exosomes, then advanced epithelial-mesenchymal transition (EMT) and angiogenesis ([@B31]). However, the current research mechanism of hsa-miR-5091 in tumors has not been reported yet, so more experiments in the future need to be carried out to hsa-miR-5091, especially in CRC.

To further understand the regulatory mechanism of the five-miRNA signature in colorectal cancer, the target genes of five miRNAs in the model were predicted by three target gene prediction databases. At the same time, based on the study of colorectal cancer, we obtained the intersection of the target genes of these miRNAs and the differentially expressed genes from the TCGA database, and performed functional enrichment analysis on these intersection genes. The GO annotation of the target genes was mainly associated with axon development, axonogenesis and stem cell differentiation, synaptic membrane, postsynaptic membrane, and neuronal cell body, metal ion transmembrane transporter activity, transcriptional activator activity and DNA binding, ion channel binding. The signal pathways of the target genes mainly enriched in the cGMP-PKG signaling pathway, cAMP signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction. Ren et al. illuminated that the cGMP/PKG signaling pathway played an essential role on proliferation and survival of human renal carcinoma cells ([@B32]). Park et al. displayed that the cAMP signaling pathway regulated by the Epac-Rap1-Akt pathway caused suppression of JNK-dependent HDAC8 degradation, which augments cisplatin-induced apoptosis by inhabiting TIPRL expression in lung cancer cells ([@B33]). Monteith GR reviewed that calcium signaling pathway not only played key role on proliferation, invasion and sensitivity to cell death, but also in the establishment and maintenance of multidrug resistance and the tumor microenvironment ([@B34]). These signaling pathways show their effects on tumors to varying degrees, and these three signaling pathways are only the tip of the iceberg of the target gene involved in signaling pathway, which prompts that our constructed miRNA prognosis model may be involved in the regulation of tumor signaling pathways.

In order to find key nodes of the miRNA signature model regulating colorectal cancer 10 hub genes (ESR1, ADCY9, MEF2C, NRXN1, ADCY5, FGF2, KITLG, GATA1, GRIA1, KAT2B) were screened according to Cytoscape 3.6.1 and its plug-in (degree ranking of cytoHubba). In addition, the Kaplan-Meier method showed that the expression of 18 genes (AHCYL2, AKR1B10, CBFA2T3, CCNJL, CCR9, CLIC5, DPP10, FAM46C, GATA1, IQGAP2, MAN1A1, MIER1, NR5A2, PHLPP2, PTGER4, RBM47, RPS6KA5, TSPAN11) were positively associated with survival prognosis, however the high expression of SRCIN1 shown a poorer over survival. Surprisingly, GATA1 (GATA binding protein 1) is not only a key gene in the PPI network, but also related to over survival of patients, which encodes s a protein which belongs to the GATA family of transcription factors and promoted erythroid development via adjusting the switch of fetal hemoglobin to adult hemoglobin. Wang et al. pointed out that decreased of GATA-1 was to the benefit of high expression of IRF-3 in lung adenocarcinoma cells by binding with a specific domain of IRF-3 promoter, consequently, alternating the immunomodulatory function in tumorigenesis ([@B35]). Thus, the miRNA signature may affect the survival prognosis of colorectal cancer patients and the colorectal cancer progression through regulating GATA1.

Conclusion {#s5}
==========

In summary, our study not only constructed a new predictive model of miRNA signature prognosis through miRNA mature expression profiling, but also by grouping to verify and evaluating the predictive ability of the model, the most important thing is that it can be used as an independent prognostic factors in CRC. In addition, the potential function is inferred by predicting the target genes of the model, which enhance our comprehension to tumorigenesis and progression of CRC. However, this is just a study based on the TCGA database using bioinformatics. We hope that there will be other databases and a large number of experiments to verify the feasibility of this prognostic model in the future and provide a reliable predictor and therapeutic target for CRC patients.
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